Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **pain pathway** refers to the complex network of peripheral and central neurons, molecular receptors, ion channels, and signaling mechanisms that transmit and modulate the perception of pain[1][4][5][7]. Pain signals are initiated by specialized sensory neurons known as nociceptors, which are activated by noxious (potentially damaging) stimuli—thermal, mechanical, chemical, or inflammatory. These signals travel via Aδ and C fibers to the dorsal root ganglion, enter the spinal cord (primarily the dorsal horn), and then ascend through distinct spinal tracts (neospinothalamic, paleospinothalamic, archispinothalamic) to various brain regions responsible for sensory discrimination, affective response, and modulation[1][7][4]. Molecular components of the pain pathway include numerous **GPCRs** (opioid, cannabinoid, serotonin, bradykinin, prostaglandin receptors), **ion channels** (voltage-gated sodium and calcium channels, TRPV1, TRPA1, ASIC), and **neurotransmitters** (glutamate, substance P, CGRP, serotonin, GABA)[2][3][5][6]. Inflammatory mediators released during injury further sensitize these systems, leading to pain amplification. Therapeutic intervention targets specific molecules within these pathways, not the generic "pain pathway" itself. Hence, "Pain pathway" in this context should be regarded as an umbrella term rather than a specific molecular target. It cannot be mapped to a canonical drug target entry but points to several well-defined molecular entities each responsible for discrete aspects of pain signaling and modulation.
Drugs targeting components of the pain pathway typically act via: Blockade of ion channels (e.g., sodium, calcium channels); Agonism/antagonism of GPCRs (opioid, cannabinoid, serotonin, bradykinin receptors); Inhibition of neurotransmitter release and synaptic transmission; Modulation of intracellular signaling cascades (PKA, MAPK, PI3K/mTOR); and Inhibition of inflammatory mediators (prostaglandins, cytokines).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pain pathway.